Drugmakers Lose Bid For 'Indefinite' Extension In FTC Case

Law360, New York (December 12, 2013, 5:44 PM EST) -- The Federal Trade Commission's pay-for-delay case against Actavis Inc. and other drugmakers is now set to resume nearly six months after the U.S. Supreme Court revived the suit, with a Georgia judge on Tuesday giving the defendants 21 days to respond to the watchdog's complaint.

Though the Supreme Court ruled in June that reverse payment patent settlements could be challenged under antitrust law, the Actavis case that spawned the landmark decision had been stuck in procedural limbo for months at the Eleventh Circuit. More recently, it...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.